Breast cancers receptor erbb 2. Medical search. Frequent questions

Immunohistochemitsry was used to evaluate the expression levels of EGFR, HER2, ESR1, progesterone receptor and BCL2 in tumors. (nih.gov)
The higher expression of HER2 in ESR1 T594T GG patients suggests the possibility that ESR1 gene polymorphisms accompanied by HER2 expression might influence the pathogenesis of breast cancers. (nih.gov)
Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. (medscape.com)
BACKGROUND: Approximately half of patients with high-risk HER2-positive early-stage breast cancer (ESBC) do not have pathologic complete response (pCR) after neoadjuvant therapy. (medscape.com)
RESULTS: We estimated that 9,300 people would experience incident high-risk HER2-positive ESBC in the United States in 2021 based on cancer surveillance databases, clinical trial data, and expert opinion. (medscape.com)
Blood samples from patients with metastatic breast cancer were deposited on glass slides, subjected to nuclear staining with DAPI, and reacted with fluorescent-labeled antibodies to detect CD45, cytokeratin (CK), and biomarkers of interest (AR, estrogen receptor [ER], and HER2) on all nucleated cells. (nih.gov)
Of 68 patients, 51 (75%) had at least 1 CTC, and 49 of these 51 (96%) had hormone-receptor-positive (HR+)/HER2-negative primary tumors. (nih.gov)
35. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status. (nih.gov)
Actually the HER2 positive "onco gene" is one that is "over- expressive " and causes the cancer to spread even more rapidly than those who do NOT have this problem. (cancer.org)
Actually originally it was thought that only Breast Cancer patients had this particular over-expressive onco gene , then later it was discovered that many gastric cancer patients that includes Esophageal Cancer patients were also testing positive for HER2. (cancer.org)
Despite the importance of HER2/Neu/ErbB2 and c-Met in the etiology of breast carcinomas, the molecular mechanisms by which they confer an invasive phenotype is still unclear. (ohri.ca)
Anticuerpo monoclonal humanizado contra el RECEPTOR ERBB-2 (HER2). (bvsalud.org)
A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). (bvsalud.org)
As an ANTINEOPLASTIC AGENT , it is used to treat BREAST CANCER where HER2 is overexpressed. (bvsalud.org)
We investigated the clinical impact of the expression of PTEN, p-Akt and PI3K in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab-based therapies. (uniroma1.it)
BACKGROUND: Amplification of the human epidermal growth factor receptor type 2 (HER2, also called HER2/neu) gene and overexpression of its product in breast-cancer cells may be associated with responsiveness to anthracycline-containing chemotherapy regimens. (mcmaster.ca)
CONCLUSIONS: Amplification of HER2 in breast-cancer cells is associated with clinical responsiveness to anthracycline-containing chemotherapy. (mcmaster.ca)
Background: The combination of lapatinib and oral vinorelbine for HER2 positive metastatic breast cancer (MBC) is convenient but with uncertain toxicity profiles. (tmu.edu.tw)
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. (ox.ac.uk)
Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxicity. (ox.ac.uk)
INTERPRETATION: Adding trastuzumab to chemotherapy for early-stage, HER2-positive breast cancer reduces recurrence of, and mortality from, breast cancer by a third, with worthwhile proportional reductions irrespective of recorded patient and tumour characteristics. (ox.ac.uk)
Triple-negative breast cancer (TNBC), which accounts for about 10% of all breast cancer cases, is defined by the absence of ER (estrogen receptor) and PR (progesterone receptor) expression, together with lack of HER2 (human epidermal growth factor 2 receptor) gene amplification or protein overexpression at diagnosis. (biomedcentral.com)
HSP90 is a conserved molecular chaperone that regulates the stability, activation and maturation of more than 200 client proteins including receptor tyrosine kinases (HER2, EGFR, IGF-1R, MET), transcription factors (HIF1, TP53), signalling proteins (AKT, SRC) and cell cycle regulatory proteins (CDK4, CDK6). (biomedcentral.com)
The epidermal growth factor receptor (EGFR) family, an essential component in PTKs activation, includes 4 members: human epidermal growth factor receptor (HER) 1 (also known as EGFR), HER2, HER3, and HER4. (cancerbiomed.org)
HER2 is overexpressed in approximately 20%-25% of breast cancers 7 - 9 . (cancerbiomed.org)
Overexpression of HER2 often leads to distant metastasis of breast cancers, and breast cancers often develop resistance within 1 year to the targeted drug trastuzumab 10 - 14 . (cancerbiomed.org)
In HER2- positive breast cancer, there is an amplification or overexpression of the HER2 gene, leading to increased production of the HER2 protein on the surface of cancer cells. (ijpsjournal.com)
The management of HER2-positive breast cancer involves a multimodal approach. (ijpsjournal.com)
Breast Cancer HER2 Status. (ijpsjournal.com)
Lapatinib is used to treat a certain type of breast cancer (HER2-positive). (ndclist.com)
A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR, ERBB-2) tyrosine kinases. (ndclist.com)
It is used for the treatment of advanced or metastatic breast cancer, where tumors overexpress HER2. (ndclist.com)
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. (ox.ac.uk)
INTRODUCTION: Estrogen receptor-α (ER) and human epidermal growth factor receptor 2 (HER2) positivity are inversely correlated by standard criteria. (ox.ac.uk)
However, we investigated the quantitative relation between ER and HER2 expression at both RNA and protein levels in HER2+ve and HER2-ve breast carcinomas. (ox.ac.uk)
METHODS: ER and HER2 levels were assessed with immunohistochemistry (IHC) and (for HER2) fluorescent in situ hybridization (FISH) and by quantitative reverse transcription-polymerase chain reaction (q-RT-PCR) in formalin-fixed primary breast cancers from 448 patients in the National Cancer Research Institute (NCRI) Adjuvant Breast Cancer Trial (ABC) tamoxifen-only arm. (ox.ac.uk)
In human epidermal growth factor receptor 2 (HER2+) breast cancers , neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed lower pathologic complete response ( pCR ) rates in hormone receptor (HR) positive versus negative tumors . (bvsalud.org)
ErbB2, also called Neu and Her2 (human epidermal growth factor receptor 2), is a 185 kDa type I transmembrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors for EGF superfamily growth factors. (rndsystems.com)
METHODS: The CB11 anti-HER2 monoclonal antibody and the DAKO Envision Plus system were used to evaluate HER-2 expression in 73 patients. (ox.ac.uk)
the majority of subjects in each arm had T1/2, N0, HER2-negative BC and had received (neo)adjuvant chemotherapy. (mcmaster.ca)
Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer. (cdc.gov)
HER2 (human epidermal growth factor receptor 2) is a transmembrane tyrosine kinase receptor and a member of the ErbB protein family (ie, the epidermal growth factor receptor [EGFR] family). (medscape.com)
HER2 gene product is overexpressed in 18-20% of invasive breast cancers. (medscape.com)
HER2 status should be determined in all patients with invasive breast cancer on the basis of 1 or more test results. (medscape.com)
Since 2017, the US Food and Drug Administration (FDA) has approved 4 biosimilars of trastuzumab (Herzuma, Ogivri, Ontruzant, Trazimera) to treat HER2-overexpressed breast cancer. (medscape.com)
The EGFR is a transmembrane glycoprotein, which belongs to the erbB family of closely related cell membrane receptors that include EGFR (erbB-1 or HER1), erbB-2 (HER2), erbB-3 (HER3), and erbB-4 (HER4). (japsonline.com)
In some men with breast cancer, the cancer cells have too much of a growth-promoting protein known as HER2 (or HER2/neu) on their surface. (cancer.org)
These cancers, known as HER2-positive breast cancers , tend to grow and spread more aggressively. (cancer.org)
In this case, they attach to the HER2 protein on cancer cells, which can help stop the cells from growing. (cancer.org)
This monoclonal antibody can be used along with chemo to treat advanced breast cancer, typically after at least 2 other drugs that target HER2 have been tried. (cancer.org)
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy. (unc.edu)
estrogen (ER) receptor for the choice of endocrine therapy, and the growth factor receptor (HER2) for anti-HER2 therapy. (lu.se)
Medscape recently asked breast cancer experts how they sequence targeted agents for HR+, HER2/neu-negative (also known as ErbB-2) metastatic breast cancer. (medscape.com)

Human epidermal growth factor receptor-2 (HER-2) tyrosine kinase inhibitors (TKI) is the targeted drug of HER-2-positive breast cancer. (nih.gov)
The ErbB proteins are a family of receptor kinases that include four closely related members: epidermal growth factor receptor (EGFR/ErbB1), ErbB2/neu, ErbB3, and ErbB4. (cdc.gov)
It is closely related instructure to the epidermal growth factor receptor. (ihcworld.com)
The epidermal growth factor (EGF) family of ligands and receptors interact to influence cell division, differentiation and motility. (biomedcentral.com)
Confocal immunofluorescence and GST pulldown assays were used to demonstrate the interaction between SHP-1 and epidermal growth factor receptor, as well as its downstream pathways. (cancerbiomed.org)
The studies are about SKBR3 and T47D, two human breast cancer cells which proved to be sensitive and resistant against the particular Epidermal Growth Factor Receptor (EGFR)/ErbB-2 receptor tyrosine kinase inhibitor pelitinib (EKB-569, Wyeth). (univie.ac.at)
Epidermal growth factor receptor tyrosine kinase inhibitor, an oral administration of small molecules. (dingminpharmaceutical.com)
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. (unc.edu)
Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma. (cancerindex.org)
In addition, it has been found that the epidermal growth factor receptor gene (EGFR) is frequently over-expressed and amplified in primary GBs. (cancerindex.org)
Virtual screening was carried out through docking the designed compounds into the ATP binding site of epidermal growth factor receptor (EGFR) to predict if these compounds have analogous binding mode to the EGFR inhibitors. (slideshare.net)
For example, the epidermal growth factor (EGF) receptor tyrosine kinases of the erbB family (which includes erbB1eerbB4) is frequently expressed at high levels in certain carcinomas and shows an inverse correlation with survival (particularly breast, colon and bladder cancers) [2]. (slideshare.net)

39. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. (nih.gov)
Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro. (cdc.gov)
Overexpression of ErbB proteins in breast cancer patients is generally associated with poor prognosis. (cdc.gov)
Overexpression of c-erbB-2 mRNA in tumor tissue was associated with a shorter survival of patients with primary ovarian cancer (P = 0.0001, N = 77) and was an independent prognostic factor in the proportional-hazard model (P = 0.035). (thieme-connect.de)
In addition, the application of a standard chemotherapy improved the survival of patients with relatively low c-erbB-2 expression (P = 0.013), but not of patients with overexpression of c-erbB-2 (P = 0.359). (thieme-connect.de)
Overexpression of the ERBB2 proto-oncogene is associated with amplification of the gene in breast cancer but increased activity of the promoter also plays a significant role. (biomedcentral.com)
Overexpression of HER-2/neu protein was more common in tissues from breast tumors than in benign breast tissue samples. (oncolink.org)
Overexpression of ErbB-2, a member of ErbB family of receptor tyrosine kinases, occurs in 15 20% of breast cancers (BC) and is considered a major oncogenic driver. (oncology-abstracts.org)
The reviewed research data implies that these co-therapies exhibited a synergistic effect on various cancer cells, where apigenin sensitized the chemo drug through different pathways including a significant reduction in overexpressed genes, AKT phosphorylation, NFκB, inhibition of Nrf2, overexpression of caspases, up-regulation of p53 and MAPK, compared to the monotherapies. (biomedcentral.com)
Mainly used for joint card of capecitabine in the treatment of erbB-2 overexpression, who previously received including anthracyclines and paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. (dingminpharmaceutical.com)
The expression and overexpression of EGFR are observed in many human solid tumors including breast, ovarian, non-small cell lung (NSCLC), colorectal, and head and neck cancers. (japsonline.com)

A (T594T) single nucleotide polymorphisms with breast cancer risk and prognosis in Tunisian patients. (nih.gov)
The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen. (nih.gov)
26. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. (nih.gov)
In the case of breast cancer, expression determined by immunohistochemistry has been shown to be associated with poor prognosis. (ihcworld.com)
Due to the lack of effective therapies and poor prognosis in TNBC (triple-negative breast cancer) patients, there is a strong need to develop effective novel targeted therapies for this subtype of breast cancer. (biomedcentral.com)
Therefore, the present investigation indicates that the negative ER, single expression of c-erbB-2 and co-expression of EGF-R and TGF-alpha are important markers which contribute indirectly to prognosis, which reconfirms previous findings on the former two while adding the new finding that immunohistochemical demonstration of expression of EGF-R and TGF-alpha may provide useful information for selecting the appropriate treatment. (kagoshima-u.ac.jp)
Diet has been shown to influence breast cancer incidence, recurrence, and prognosis. (mdpi.com)
Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis. (ox.ac.uk)
BACKGROUND: HER-2 (c-erbB2/Neu) predicts the prognosis of and may influence treatment responses in breast cancer. (ox.ac.uk)
HER-2 as a predictor of poor prognosis may partly relate to its ability to influence the relocalisation of p21WAFI/CIPI from the nucleus to the cytoplasm, resulting in a loss of p21WAFI/CIPItumour suppressor functions. (ox.ac.uk)
In colon cancer, some reports have mentioned that high Ki67 expression was associated with poor prognosis ( 7 , 8 ), while others reported the opposite conclusion, showing that high Ki67 expression reflected improved clinical outcome ( 9 , 10 ). (spandidos-publications.com)

We found no evidence for an association between EGFR R521K polymorphism and breast cancer risk. (nih.gov)
28. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. (nih.gov)
34. Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer. (nih.gov)
Immunohistochemistry and The Cancer Genome Atlas database were used to investigate the clinical association between SHP-1 and EGFR in human breast cancer. (cancerbiomed.org)
SHP-1 expression was associated with better survival in patients with breast cancer, whereas SHP-1 expression was negatively correlated with EGFR in human breast cancer. (cancerbiomed.org)
SHP-1 is an important prognostic biomarker in patients with breast cancer, and the SHP-1-EGFR axis is a promising target for treatment. (cancerbiomed.org)
Die Diplomarbeit handelt von zwei Brustkrebszellinien SKBR3 und T47D, die entweder resistent oder sensibel gegenüber dem EGFR/ErbB-2 Tyrosinkinase Inhibitor Pelitinib sind. (univie.ac.at)

Circulating tumor cells (CTCs) can serve as prognostic and diagnostic tools, prompting us to measure AR protein expression and conduct genomic analyses on CTCs in patients with metastatic breast cancer. (nih.gov)
The prognostic significance of recent tumor markers for lymph node negative breast cancer]. (nih.gov)
24. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma]. (nih.gov)
30. Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies. (nih.gov)
Both epidemiological and experimental studies indicate that ethanol is a tumor promoter and may promote metastasis of breast cancer. (cdc.gov)
Mutations in the p53 tumor suppressor gene and accumulation of its protein in breast tissue are thought to play a role in breast carcinogenesis. (hindawi.com)
The actual sequence of genetic and molecular changes underlying the progression from normal breast tissue to invasive cancer has not been characterized, but the p53 tumor suppressor gene is thought to play a role [ 4 ]. (hindawi.com)
Tumor specimens from 160 patients with breast cancer and 160 noncancerous tissues were used to examine the expression of SHP-1 and to analyze its association with overall survival through Kaplan-Meier and multivariate Cox regression analyses. (cancerbiomed.org)
In this review, we focused on combination therapy, particularly with apigenin augmenting the anti-cancer effects of chemo drugs on tumor cells, reduce their side effects, subdue drug resistance, and protect healthy cells. (biomedcentral.com)
[ 1 ] Activation of this class of cellular receptors is known to result in increased activity of a variety of molecular pathways associated with tumor growth and progression. (medscape.com)
Weak relationships were found between c-myc amplification and the presence of lymph-node metastasis, advanced stage, DNA non-diploidy and premenopausal status, but not tumor size, estrogen receptor or progesterone receptor status, or int-2 amplification. (lu.se)
DESCRIPTION (Applicant's Description) Evidence for biological synergism of plasma-membrane tyrosine kinase receptors erbB-3 and erbB-2 in model systems and human breast tumor cell lines raises the possibility that coexpression of these receptors may play a role in tumorigenesis and cell proliferation. (cancer.gov)
Thus, identifying coexpressing erbB-2 and erbB-3 receptors in tumor specimens will provide greater specificity, and might identify a subpopulation of patients with different outcome and chemotherapeutic potential. (cancer.gov)
Therefore, our specific aims are: (1) to perform immunostaining of erbB-3 in transfected and tumor cell lines using five different erbB-3 antibodies, (2) to localize the cell fraction in which erbB-3 resides in these cell lines, and (3) to compare the pattern of staining of those antibodies in tumor specimens. (cancer.gov)
The traditional prognostic factors based on morphological features or blood markers are not sufficient to stratify the risk of post-operative tumor progression ( 2 ). (spandidos-publications.com)

This is a unique case due to the low frequency 2 , the atypical clinical history, but mainly the difficult histopathological differential diagnosis and immunohistochemical evaluation among these neoplasms. (bvsalud.org)

36. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. (nih.gov)
We investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer recurrence and cause-specific mortality. (ox.ac.uk)
Trastuzumab: updated mechanisms of action and resistance in breast cancer. (ijpsjournal.com)
Despite clinical efficiency of ErbB-2-targeted therapies (e.g. trastuzumab), resistance to said drugs is a major issue. (oncology-abstracts.org)
Trastuzumab can be used to treat both early-stage and advanced breast cancer. (cancer.org)
This monoclonal antibody can be given with trastuzumab and chemo, either before or after surgery to treat early-stage breast cancer, or to treat advanced breast cancer. (cancer.org)

23. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features. (nih.gov)
Small interfering RNAs (siRNAs) can be targeted to tumors and one example is the suppression of H-ras gene expression indicating the potential for application in therapy of ovarian cancer. (researchandmarkets.com)
Women with HER-2/neu gene amplification in their malignant tumors were also likely to have HER-2/neu gene amplification in earlier, benign breast samples. (oncolink.org)
An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors. (cdc.gov)
However, the existing clinical studies are weak, and the data on expression of erbB-3 in breast tumors are inconsistent. (cancer.gov)
The goal of this proposal is to validate reagents for detection of erbB-3 expression by immunohistochemistry in paraffin sections of breast tumors. (cancer.gov)
Adjuvant chemotherapy with the regimens of FOLFOX, XELOX or capecitabine alone was performed for patients with lymph node metastasis and those with high-risk microsatellite stable stage II tumors, including patients with perforated tumors, pT4N0 lesions, vascular invasion and/or bowel obstruction ( 13 ), following the NCCN guidelines of colon cancer (Version 3.2022). (spandidos-publications.com)

Particularly, ErbB2 plays a pivotal role in ErbB-mediated activities. (cdc.gov)
Human breast cancer cells or mammary epithelial cells with a high expression of ErbB2 exhibited an enhanced response to ethanol-stimulated cell invasion in vitro. (cdc.gov)
ErbB2 is widely expressed in epithelial cells and plays roles in development, cancer, communication at the neuromuscular junction, and regulation of cell growth and differentiation. (rndsystems.com)
The following product was used in this experiment: ErbB2 (HER-2) Polyclonal Antibody from Thermo Fisher Scientific, catalog # PA5-16305, RRID AB_10983296. (thermofisher.com)

32. p53 and c-erbB-2 protein expression in breast carcinomas. (nih.gov)
c-erbB-2 oncoprotein is detectable in a proportion of breast and other adenocarconomas, as well as transitional cell carcinomas. (ihcworld.com)
The data suggest that topoisomerase IIα, which correlates with c-erbB-2 expression, contributes to the resistance of c-erbB-2 -overexpressing carcinomas. (thieme-connect.de)
1989). ER expression was biochemically recognized in 43.4% of mammary carcinomas, and EGF-R, EGF, TGF-alpha and c-erbB-2 were histochemically recognized in 25.3, 14.5, 27.7 and 18.0% of mammary carcinomas examined respectively, using conventional sections of buffered formalin-fixed, paraffin-embedded tissue and monoclonal or polyclonal antibodies. (kagoshima-u.ac.jp)

2 Bargmann C I, Hung M C, Weinberg R A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p183. (thieme-connect.de)
8 Di-Fiore P P, Pierce J H, Kraus M H, Segatto O, King C R, Aaronson S A. c-erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. (thieme-connect.de)
Herceptin is the first therapy for breast cancer which targets an oncogene product. (biomedcentral.com)
The HER-2/neu oncogene (also called c-erbB-2) codes a surface membrane protein that interacts with the epithelial growth factor receptor. (oncolink.org)
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. (ijpsjournal.com)
The c-myc proto-oncogene was analyzed in 311 cases of primary breast cancer, in 8% of which it was found to be amplified, usually at moderately increased copy number (2-5 copies). (lu.se)
C-myc amplification was significantly correlated to a high S-phase fraction and to amplification of the c-erbB-2 proto-oncogene. (lu.se)

In the present study, we examined die role of c-erbB-2 for chemoresistance in ovarian cancer. (thieme-connect.de)
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. (ijpsjournal.com)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. (ijpsjournal.com)

Mounting evidence suggests that cancer results from a series of mutations in genes involved in cell growth and differentiation, DNA repair, and cell cycle control [ 1 , 2 ]. (hindawi.com)
Cancer progression from a localized neoplastic lesion to an invasive phenotype involves genetic changes resulting in the activation of several genes implicated in proliferation and cell invasion. (ohri.ca)
Hallazgos recientes justifican un renovado interés en este proceso, el cual se estima que afecta más del 95% de los genes humanos. (uba.ar)
Encontramos que el cloroplasto responde a la luz generando una señal retrógrada que actúa en el núcleo en la regulación del splicing alternativo de determinados genes. (uba.ar)
Single nucleotide polymorphisms in the p21 and bcl2 cancer susceptibility genes and breast cancer risk in Saudi Arabia. (cdc.gov)

1 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America. (nih.gov)
3 Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China. (nih.gov)
Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova. (bvsalud.org)

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. (cdc.gov)
Endocrine therapy as second-line treatment is generally fulvestrant although you can use a different AI, tamoxifen (selective estrogen receptor modulator), etc. (medscape.com)

Our research efforts are also focused on understanding how growth factor receptors such as ErbB-2 (overexpressed in 25-30% of human breast cancers) and c-Met are coupled to extracellualr matrix signaling and to the migration machinery using transgenic models and cell culture systems. (ohri.ca)

MATERIALS AND METHODS: We used decision-modeling techniques to simulate recurrence, progression from locoregional to distant cancer, breast cancer-related mortality, and mortality from other causes over a 10-year period in a hypothetical cohort. (medscape.com)
This residual disease burden resulted in 6,435 life-years lost versus the recurrence-free cohort, and healthcare-related costs totaling $644 million, primarily associated with treating distant cancers. (medscape.com)
We collected individual patient-level data on baseline characteristics, dates and sites of first distant breast cancer recurrence and any previous local recurrence or second primary cancer, and the date and underlying cause of death. (ox.ac.uk)
Primary outcomes were breast cancer recurrence, breast cancer mortality, death without recurrence, and all-cause mortality. (ox.ac.uk)
The proportional reduction in recurrence was largest in years 0-1 after randomisation (0·53, 99% CI 0·46 to 0·61), with benefits persisting through years 2-4 (0·73, 0·62 to 0·85) and 5-9 (0·80, 0·64 to 1·01), and little follow-up beyond year 10. (ox.ac.uk)
Given the high rates of recurrence and metastasis, novel therapeutic treatments for breast cancer that are effective and safe are urgently needed. (cancerbiomed.org)
C-myc amplification, and especially a high gene copy number (greater than 5 copies), was significantly related to early recurrence and death in breast cancer, a relationship seen in both the lymph-node-negative and node-positive subcategories. (lu.se)

CTC enumeration and analysis using no enrichment or selection provides a non-biased approach to detect AR expression and chromosomal aberrations in CTCs in patients with metastatic breast cancer. (nih.gov)

Several studies have reported an association between HER-2/neu amplification and both earlier relapse and decreased survival in patients with breast cancers. (oncolink.org)
This study assessed the amplification of the HER-2/neu gene in BBL and risk of subsequent breast cancer. (oncolink.org)
Low-level HER-2/neu amplification was detected in 4.5% of benign biopsies from control women, compared with 9.5% of benign tissues and 18% of malignant tissues from breast cancer patients. (oncolink.org)
In women with both HER-2/neu amplification and a proliferative histopathologic diagnosis, the risk of breast cancer was increased more than seven-fold. (oncolink.org)
Genetic alterations, including HER-2/neu gene amplification, may occur as relatively early events in the development of breast cancer. (oncolink.org)

A were genotyped in a sample of 148 Tunisian breast cancer patients and 303 controls using PCR-RFLP method. (nih.gov)
31. Clinical and pathological factors influencing the survival of breast cancer patients with malignant pleural effusion. (nih.gov)
I've been corresponding with Esophageal Cancer patients since 2003 and by this time have come to understand quite a bit about the different types of surgery, and how different patients qualify for different kinds of treatments and/or surgery. (cancer.org)
A significant association between expression of c-erbB-2 mRNA und survival was obtained for the subgroup of patients who received a standard chemotherapy with carboplatin or cisplatin and cyclophosphamide (P = 0.0003). (thieme-connect.de)
In the Phase II study, 11 patients safely had vinorelbine escalated to 60 mg/m2 on cycle 2. (tmu.edu.tw)
Six patients had disease control over 2 years. (tmu.edu.tw)
However, both intrinsic and acquired resistance to HSP90 inhibitors (HSP90i) limits their effectiveness in cancer patients. (biomedcentral.com)
While not fatal atrial arrhythmias and AF specifically affect the grade of lifestyle of patients because of a variety of symptoms including shortness of breathing chest pains exhaustion palpitations lightheadedness as well as syncope [2]. (biopaqc.com)
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. (bvsalud.org)
The PerELISA study was aimed to evaluate the efficacy of a de-escalated, chemotherapy -free neoadjuvant regimen in HR+/HER2+ breast cancer patients selected on the basis of Ki67 inhibition after 2-week letrozole . (bvsalud.org)
PerELISA is a phase II, multicentric study for postmenopausal patients with HR+/HER2+ operable breast cancer . (bvsalud.org)
Patients received 2-week letrozole , and then underwent re- biopsy for Ki67 evaluation. (bvsalud.org)
Combinatorial therapy may be applied to cancer cell cultures, animal xenograft models, or clinical trials in cancer patients. (biomedcentral.com)
A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. (cdc.gov)
A) of B-cell lymphoma 2 gene in breast cancer patients of Mazandaran province in Northern Iran. (cdc.gov)
DNA repair and apoptosis: Roles in radiotherapy-related acute reactions in breast cancer patients. (cdc.gov)
We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. (cancer.org)
A total of 312 consecutive patients with stage I‑III colon cancer who underwent radical surgery with or without adjuvant chemotherapy were included in the present study. (spandidos-publications.com)
In conclusion, high Ki67 expression was associated with a good therapeutic outcome in patients receiving adjuvant chemotherapy in colon cancer. (spandidos-publications.com)
To investigate the prognostic significance of Ki67 in colon cancer, the associations of Ki67 expression levels with clinicopathological variables and survival data from 312 patients with colon cancer were analyzed. (spandidos-publications.com)
A total of 312 consecutive patients with stage I-III colon cancer treated at Peking University Cancer Hospital (Beijing, China) between January 2004 and December 2010 were retrospectively included. (spandidos-publications.com)
Around two thirds of all breast cancer patients are cured by surgery as single treatment modality. (lu.se)
Finding molecular signatures for the identification of patients who could be spared chemotherapy is considered to have the highest priority among breast cancer specialists world-wide. (lu.se)

22. Clinical implications of CSN6 protein expression and correlation with mutant-type P53 protein in breast cancer. (nih.gov)
An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. (nih.gov)
Antisense oligonucleotides have been in clinical trials for cancer for some time now. (researchandmarkets.com)
Role of drug delivery in the management of cancers of the brain, the bladder, the breast, the ovaries and the prostate are used as examples to illustrate different approaches both experimental and clinical. (researchandmarkets.com)
The clinical significance of HER-2/neu expression in benign breast lesions (BBL) remains unclear. (oncolink.org)
RNA sequencing data and the expression and clinical importance of SHP-1 in breast cancer were evaluated with data from The Cancer Genome Atlas. (cancerbiomed.org)
The present study examined HER-2 and p21WAFI/CIPI expression in a series of breast cancers with up to 9 years of follow-up, to evaluate whether in vitro findings were related to clinical data and the effect on outcome. (ox.ac.uk)
Nevertheless, human clinical trials are a prerequisite to consider the potential use of apigenin in the prevention and treatment of various cancers. (biomedcentral.com)
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Oct 13 (19): 5790-7. (cdc.gov)
It also evidenced the importance of the clinical history, the correct propaedeutics, and a detailed study of the breasts to arrive at the proper diagnosis, ruling out others possibilities. (bvsalud.org)
Breast cancer is a heterogeneous disease with a large variability in clinical outcome. (lu.se)

27. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. (nih.gov)
In 50 in situ breast cancers an immunohistochemical study, evaluating estrogen (ER) and progesterone (PR) receptors, Proliferation Index (PI), c-erbB-2/Neu and p53 expression was performed. (unife.it)
An immunohistochemical assessment would more accurately illustrate the importance of c-myc activation in human breast cancer. (lu.se)
Anatomopathological and immunohistochemical study revealed a preliminary diagnosis of breast carcinoma metastasis. (bvsalud.org)
New anatomopathological and immunohistochemical exams confirmed the diagnosis of breast carcinoma metastasis. (bvsalud.org)
They performed comparative studies of the cutaneous malignancy and breast nodules, especially with immunohistochemical examinations. (bvsalud.org)
The anatomopathological report indicated breast carcinoma metastasis and the pathologist recommended a further immunohistochemical investigation to determine the neoplastic site of origin. (bvsalud.org)

Innovative cancer therapies are based on current concepts of the molecular biology of cancer. (researchandmarkets.com)
siRNA-based breast cancer therapy by suppressing 17β-hydroxysteroid dehydrogenase type 1 in an optimized xenograft cell and molecular biology model in vivo. (cancerindex.org)
BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database. (cdc.gov)

The majority of tumours are invasive duct subtype and the profile of hormone receptors is positive for estrogen receptors and /or progesterone receptors in less than half of cases. (who.int)

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2 H -tetrazolium, clone formation, transwell migration, and transwell invasion assays were used to assess the proliferation, migration, and invasion ability of LSCC cells. (degruyter.com)
ErbB (also termed HER) receptors are expressed in various tissues of epithelial, mesenchymal and neuronal origin, in which they are involved in the control of diverse biological processes such as proliferation. (biomedcentral.com)
Objective: The phosphatase and tensine homologue gene (PTEN) plays a crucial role in proliferation and survival of cancer cells by antagonizing the function of phosphatidylinositol 3′-kinase (PI3K), which, in turn, results in decreased Akt activity. (uniroma1.it)
In vitro and in vivo assays were performed to elucidate the effects of SHP-1 on breast cancer cell proliferation and invasion. (cancerbiomed.org)
Ectopic SHP-1 expression significantly suppressed breast cancer cell proliferation, migration, and invasion. (cancerbiomed.org)
Hormone-dependent breast cancer is the most common form of breast cancer, and inhibiting 17β-HSD1 can play an attractive role in decreasing estrogen and cancer cell proliferation. (cancerindex.org)
Using immunohistochemistry we are, in clinically well-defined materials, evaluating the importance of, for example: biomarkers involved in proliferation, the mTOR signaling pathway, ALDH1 (a stem cell marker), IGF1R, AIB1 (a co-factor for ER) and GPER1 (G- protein-coupled estrogen receptor) as well as apoptotic markers. (lu.se)

Androgen receptor (AR) is frequently detected in breast cancers, and AR-targeted therapies are showing activity in AR-positive (AR+) breast cancer. (nih.gov)
Profiles of 238 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 291 collaborations. (researchandmarkets.com)

Standard intention-to-treat log-rank analyses, stratified by age, nodal status, oestrogen receptor (ER) status, and trial yielded first-event rate ratios (RRs). (ox.ac.uk)

Using this knowledge, we can establish a valid protocol for quantitating erbB-3 in breast cancer an evaluating its etiologic prognostic significance. (cancer.gov)

The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance. (researchandmarkets.com)
METHODS: In the randomized, controlled Mammary.5 trial, we studied 639 formalin-fixed paraffin-embedded specimens obtained from 710 premenopausal women with node-positive breast cancer who had received either cyclophosphamide, epirubicin, and fluorouracil (CEF) or cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant chemotherapy. (mcmaster.ca)
Lapatinib is used with capecitabine (Xeloda) to treat a certain type of advanced breast cancer in people who have already been treated with other chemotherapy medications. (ndclist.com)
Therapeutic resistance to radiation and chemotherapy is one of the major obstacles in cancer treatment. (biomedcentral.com)

We previously showed that higher levels of cytoplasmic p21WAFI/CIPI in breast cancers predicted reduced survival at 5 years. (ox.ac.uk)

A Fab fragment of the chimeric monoclonal antibody 7E3 that binds to the glycoprotein IIb-IIIa receptor of human platelets, and blocks PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX, potently inhibiting PLATELET AGGREGATION. (nih.gov)
25. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. (nih.gov)
All the synthesized compounds were evaluated for in vitro anticancer activity employing 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay against human adenocarcinoma (HT-29), breast cancer (MDA-231), and Ehrlich ascites carcinoma cell lines. (japsonline.com)
Synthetic peptide derived from C-terminus of human c-erbB-2/HER-2 protein. (thermofisher.com)
PA5-16305 targets HER-2 in IHC (P), IP, and WB applications and shows reactivity with mouse, Non-human primate, Rat, and Human samples. (thermofisher.com)
The PA5-16305 immunogen is synthetic peptide derived from C-terminus of human c-erbB-2/HER-2 protein. (thermofisher.com)
0.1 nM) and selective in vitro antitumor properties in human cancer cell lines (e.g.,colon, nonsmall e celllungandbreastsubpanels)oftheNational Cancer Institute (NCI) 60 human cancer cell line screen [15] and also exhibited remarkable antitumor activity against malignant cell lines [16]. (slideshare.net)

Taken together, these findings suggest that p53 changes may play a role in the pathogenesis of breast cancer. (hindawi.com)

This humanized antibody to HER-2 has been shown to have activity as a single agent in a phase II trial of heavily pre-treated. (biomedcentral.com)

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (ijpsjournal.com)

Lapatinib, pyrotinib and neratinib, as ErbB family TKIs, have been approved by National Medical Products Administration and applied in the treatment of HER-2 positive breast cancer in China. (nih.gov)

HER-2 activity induces the cytoplasmic location of p21WAFI/CIPI in cell culture, accompanied by resistance to apoptosis. (ox.ac.uk)
This review explicates the combinatorial strategies involving apigenin to overcome drug resistance and boost the anti-cancer properties. (biomedcentral.com)

A carcinoma originating in the lung and the most common lung cancer type in never-smokers. (nih.gov)
In the case of breast cancer, a series of genetic changes that develop over time is believed, in most cases, to drive the morphologic progression from proliferative disease without atypia to atypical ductal hyperplasia and then to ductal carcinoma in situ and ultimately invasive ductal carcinoma [ 3 ]. (hindawi.com)
Although the patient had no medical history of breast cancer, due to this result, she was referred to a mastologist, who investigated her breast nodules for the possible primary focus of the carcinoma. (bvsalud.org)
breast carcinoma, sweat gland carcinoma, skin cancer. (bvsalud.org)
Apocrine skin carcinoma has characteristics similar to those of cutaneous breast carcinoma metastases when it presents a tubule-lobular, or cordonal differentiation. (bvsalud.org)
Carcinoma of the breast is the most prevalent cancer among Egyptian women and constitutes 29% of National Cancer Institute cases. (who.int)

Eine signifikante Assoziation bestand zwischen der Expression von c-erbB-2 mRNA und Überleben in der Subgruppe der Patientinnen, die eine Standardchemotherapie mit Cisplatin/Carboplatin und Cyclophosphamid erhalten hatten (p = 0,0003). (thieme-connect.de)
Darüber hinaus verbesserte die Applikation einer Standardchemotherapie das Überleben in der Subgruppe der Patientinnen mit geringer Expression von c-erbB-2 mRNA (p = 0,013), aber nicht in der Subgruppe der Patientinnen mit hoher Expression von c-erbB-2 mRNA (p = 0,359). (thieme-connect.de)
Die Expression der c-erbB-2 mRNA korrelierte mit der Expression der mRNA von Topoisomerase IIα (p = 0,009), aber nicht mit der Expression der mRNA von Topoisomerase IIβ (p = 0,221). (thieme-connect.de)
Die Daten stützen die Hypothese, dass Topoisomerase IIα, das mit der Expression von c-erbB-2 korreliert, an der Entwicklung der Resistenz c-erbB-2 -exprimierender Tumoren beteiligt ist. (thieme-connect.de)
Expression of c-erbB-2 mRNA correlated with expression of topoisomerase IIα mRNA determined by a reverse semiquantitative PCR technique (P = 0.009), whereas expression of c-erbB-2 und topoisomerase IIβ mRNA dit not correlate (P = 0.221). (thieme-connect.de)
The investigators measured HER-2/neu gene expression in benign and malignant breast tissues from 137 women with BBL who subsequently developed breast cancer, and in benign tissue from 156 controls with BBL who did not develop cancer. (oncolink.org)
There was a much weaker association between nuclear p21WAFI/CIPI and HER-2 expression (P = 0.05), suggesting an inverse relationship between nuclear p21WAF1/CIP1 and HER-2. (ox.ac.uk)
A promoter polymorphism and BCL2 gene expression on the progression of breast cancer. (cdc.gov)
Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples. (cdc.gov)

However, apigenin may perform synergistically by different cell signaling pathways, including down-regulation/up-regulation of transcription factors, activate/deactivate membrane receptors, cell signaling regulatory components, and apoptosis cascades. (biomedcentral.com)

p53 nucleotide changes overall were not associated with risk [ 31 ], whereas nonpolymorphic intronic changes in p53 were associated with increased risk of progression to invasive breast cancer [ 31 ]. (hindawi.com)
They have been shown to be key regulators of normal cellular processes and additionally play a critical role in the development and progression of many types of cancer [1]. (slideshare.net)

We studied the subgroup of postmenopausal hormone receptor-negative BC subjects not receiving endocrine treatment who provided fasting blood at baseline and at 6 months after being randomly assigned. (mcmaster.ca)

Most previous studies of p53 in benign breast tissue have examined the prevalence of p53 immunopositivity and/or p53 mutations in case series, often involving only a limited number of cases [ 24 - 29 ]. (hindawi.com)

In two previous studies, we showed that women who were immunopositive for p53 in normal or benign breast tissue had a 2- to 2.5-fold increased risk of developing subsequent invasive breast cancer [ 30 , 31 ]. (hindawi.com)

This novel irreversible ErbB inhibitor showed effects on the growth activity and on ErbB-triggered signaling. (univie.ac.at)

These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods. (researchandmarkets.com)
Important methods of immunotherapy in cancer involve the use of cytokines, monoclonal antibodies, cancer vaccines and immunogene therapy. (researchandmarkets.com)
Several innovative methods of drug delivery are used in cancer. (researchandmarkets.com)
Fruits, vegetables and endometrial cancer risk in women in the European forces in synthesizing evidence on new methods for the risk of cancer: a multisite case-control study in Prospective Investigation into Cancer and Nutrition cervical cancer prevention. (who.int)

Anatomy13

Organisms3

Diseases45

Chemicals and Drugs62

Analytical, Diagnostic and Therapeutic Techniques and Equipment72

Psychiatry and Psychology3

Phenomena and Processes51

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena2

Humanities1

Information Science7

Named Groups3

Health Care32

Geographicals2

HER253

Epidermal growth12

Overexpression11

Prognosis11

EGFR7

Tumor15

Neoplasms1

Trastuzumab6

Tumors7

ERBB24

Carcinomas4

Oncogene7

Ovarian cancer3

Genes5

Oncology3

Tamoxifen2

Growth factor receptors1

Recurrence7

Metastatic breast1

Amplification5

Patients23

Clinical11

Immunohistochemical7

Molecular3

Estrogen Receptors1

Proliferation7

Therapies2

Oestrogen receptor1

Prognostic significance1

Chemotherapy4

Survival1

Human7

Pathogenesis of breast1

Antibody1

Mortality1

Lapatinib1

Resistance2

Carcinoma6

Expression9

Apoptosis1

Progression2

Postmenopausal1

Prevalence1

Tissue1

Inhibitor1

Methods4